Want to see TSE:XLY full AI Analyst Report?
Top Page
Auxly Cannabis Group
(TSX:XLY)
Select Model
Select Model
Rating:78Outperform
Price Target:
C$3.50
▲(1844.44% Upside)
Action:Reiterated
Date:07/29/26
The score is primarily supported by strong improving fundamentals (profitability and cash flow recovery alongside reduced leverage). Valuation adds support via a low P/E, while technicals are positive based on moving-average trends but are less conclusive due to missing RSI/MACD/Stochastic data.
Positive Factors
Revenue Growth Momentum
Auxly’s multi-year revenue recovery to C$158.6M TTM and ~22% revenue growth indicate expanding product distribution and market traction in Canada. A sustained top-line uptrend supports scale benefits, better retailer shelf presence, and durable revenue diversification across formats over the next several months.
Negative Factors
Margin Moderation
Reported margin compression in the TTM period versus 2025 suggests the pace of profitability improvement is slowing. If pricing pressure, mix shifts toward lower‑margin products, or higher compliance costs persist, margin resilience and the ability to sustain free cash flow gains could be structurally impaired.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth Momentum
Auxly’s multi-year revenue recovery to C$158.6M TTM and ~22% revenue growth indicate expanding product distribution and market traction in Canada. A sustained top-line uptrend supports scale benefits, better retailer shelf presence, and durable revenue diversification across formats over the next several months.
Read all positive factors
Auxly Cannabis Group (XLY) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$333.89M
Dividend YieldN/A
Average Volume (3M)979.68K
Price to Earnings (P/E)8.7
Beta (1Y)0.81
Revenue Growth22.20%
EPS Growth47.29%
CountryCA
Employees446
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.35
Shares Outstanding103,370,320
10 Day Avg. Volume1,296,089
30 Day Avg. Volume979,678
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)1.09
Price to Sales (P/S)1.27
P/FCF Ratio8.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
C$0.25Price Target Upside38.89% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.14
Revenue Forecast (FY)C$164.50M
Auxly Cannabis Group Business Overview & Revenue Model
Company Description
Auxly Cannabis Group Inc. operates as a Canadian consumer packaged goods (CPG) firm focused on the cannabis market. Its primary activities include the development, manufacturing, and distribution of cannabis products, targeting both recreational a...
How the Company Makes Money
Auxly primarily makes money by selling cannabis products into the Canadian legal market. Its main revenue stream is the wholesale sale of branded finished goods (e.g., dried flower, pre-rolls, vape products, extracts, and edibles) that are distrib...
Auxly Cannabis Group Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
74
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 158.57M | 151.48M | 122.33M | 101.08M | 94.47M | 83.83M |
| Gross Profit | 75.39M | 86.74M | 59.93M | 21.28M | 16.51M | 19.29M |
| EBITDA | 49.15M | 50.30M | 24.38M | -10.89M | -94.79M | -18.30M |
| Net Income | 33.21M | 41.85M | -16.35M | -44.51M | -130.29M | -33.74M |
Balance Sheet | ||||||
| Total Assets | 279.68M | 271.64M | 261.53M | 261.90M | 331.82M | 450.42M |
| Cash, Cash Equivalents and Short-Term Investments | 43.06M | 32.67M | 18.50M | 15.75M | 14.78M | 14.89M |
| Total Debt | 55.78M | 57.65M | 68.47M | 159.04M | 193.59M | 190.10M |
| Total Liabilities | 95.92M | 94.06M | 145.87M | 210.86M | 246.13M | 242.31M |
| Stockholders Equity | 183.76M | 177.58M | 115.66M | 51.05M | 90.41M | 212.52M |
Cash Flow | ||||||
| Free Cash Flow | 32.71M | 23.37M | 14.02M | 6.61M | -11.67M | -50.01M |
| Operating Cash Flow | 35.98M | 25.89M | 16.78M | 8.21M | -2.48M | -49.63M |
| Investing Cash Flow | -3.71M | -2.46M | -445.00K | -1.56M | 1.18M | 17.33M |
| Financing Cash Flow | -6.97M | -9.81M | -13.59M | -5.68M | 1.18M | 26.40M |
Auxly Cannabis Group Technical Analysis
Positive
0.18
Price Trends
2.53
Positive
2.24
Positive
2.10
Positive
Market Momentum
0.17
Negative
63.21
Neutral
79.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:XLY, the sentiment is Positive. The current price of 0.18 is below the 20-day moving average (MA) of 2.72, below the 50-day MA of 2.53, and below the 200-day MA of 2.10, indicating a bullish trend. The MACD of 0.17 indicates Negative momentum. The RSI at 63.21 is Neutral, neither overbought nor oversold. The STOCH value of 79.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:XLY.
Auxly Cannabis Group Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
78 Outperform | C$333.89M | 8.70 | 19.79% | ― | 22.20% | 47.29% | |
75 Outperform | C$1.63B | 16.86 | 6.46% | ― | 36.21% | 264.71% | |
54 Neutral | C$250.99M | -9.51 | -6.83% | ― | 38.14% | 2030.00% | |
52 Neutral | C$638.00M | -2.11 | -35.48% | ― | 6.81% | 85.26% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | C$343.12M | -2.73 | -21.00% | ― | -18.93% | -472.15% |
* Healthcare Sector Average
TSE:XLY
Auxly Cannabis Group
3.01
0.70
30.30%
TSE:WEED
Canopy Growth
1.41
-0.65
-31.55%
TSE:OGI
Organigram Global
1.75
-0.39
-18.22%
TSE:ACB
Aurora Cannabis
5.27
-2.16
-29.07%
TSE:CRON
Cronos Group
4.41
0.94
27.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.